Conference abstractPublished 1 Sep 2015
Development of a novel IHC based test for prediction of risk of recurrence for breast cancer patients
OncoStem Diagnostics Pvt. Ltd., India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Estimation of risk of distant recurrences in breast cancer patients based on biomarkers beyond current gold standard e.g. ER, PR, Her2, node status and Stage to influence treatment decision is of critical importance. At present there are a few molecular tests viz oncotype dx, mamma-print available for patients with ER+, node and HER2 negative, Stage 1 tumors for prediction of risk of recurrence. However use of these tests in India is very minimal as >70% of patients get diagnosed in node+, Stage 2 disease and due to cost constraints. We decided to develop an Immunohistochemistry based prognostic test to predict ‘risk of recurrence’ for ER+ patients in Stage 1-2. To this aim we carried out a retrospective, non-interventional, anonymized study on 420 left over breast FFPE tumor samples of Stage 1-3 with known outcomes about distant recurrence in first 5 years. We tested about 25 different biomarkers via immunohistochemistry belonging to multiple pathways: Proliferation, resistance, quiescence, adhesion etc. Statistical analysis finalized an algorithm with 6 biomarkers which predicts risk of recurrence as low or high for each patient. Early validation on ~200 cases shows 95% specificity and 54% sensitivity of prediction. Our biomarkers are targetable as they are membrane associated and thus in future high risk patients will be treated with new targeted drugs to reduce risk of recurrence. Thus, we believe we have developed a simple, inexpensive and highly specific test useful to majority of breast cancer patients across the globe with high specificity and sensitivity. We would like to describe the details of development of the test in my talk.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Manjiri Bakre”